Developer docs
API playgroundTry for free, no card

Search company profiles

ESTEVE

Full company profile

uuid0008pqc

Namestring
ESTEVE
Legal namestring
ESTEVE
Websiteurl
esteve.es
Company typeenum
Private
Founded yearint
1996
Descriptiontext

ESTEVE is a privately held Spanish specialty pharmaceutical company headquartered in Barcelona that operates a dual-engine business model combining proprietary pharmaceutical products with contract development and manufacturing (CDMO) services. The company employs between 1,001 and 5,000 people and reported €828 million in 2025 net revenue (+14% YoY) alongside €151 million in EBITDA (+19% YoY) at an 18% margin, with management targeting €1 billion in revenue by 2027.

On the pharmaceutical side, ESTEVE commercializes specialty medications across rare diseases (Cushing's syndrome, adrenocortical carcinoma via the HRA Pharma Rare Diseases portfolio acquired from Perrigo in 2024), infusion therapies (Prialt for severe chronic pain and Quzyttir for acute urticaria, consolidated globally via the March 2026 TerSera acquisition), and supportive cancer care (AKYNZEO and ALOXI for chemotherapy-induced nausea and vomiting, distributed in DACH markets under a 15-year partnership with Helsinn Healthcare). The company sells these products through a direct enterprise sales force covering seven European markets — Spain, France, Germany, Italy, Portugal, the UK, and Benelux — and is now expanding into the United States following the TerSera acquisition.

On the CDMO side, ESTEVE CDMO is a global pure-play contract development and manufacturing organization specializing in high-quality small-molecule active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and high-potency APIs (HP APIs) used in oncology and hormonal therapies. Capabilities were significantly expanded through the July 2025 acquisition of U.S.-based Regis Technologies and a $15.5 million investment in the Morton Grove, Illinois facility announced in March 2026, alongside the addition of spray dryers and containment capabilities at the Celrà, Girona, Spain site. The company has cumulatively deployed approximately €500 million in inorganic investments over two years, is partially owned (26% stake) by German private investment firm Lubea since May 2023, and achieved B Corp Certification in January 2026.

Short descriptiontext

ESTEVE is a Barcelona-based private specialty pharmaceutical company operating a dual-engine model: proprietary drugs in rare diseases, infusion therapies, and supportive cancer care, plus a global CDMO business specializing in small-molecule APIs and high-potency APIs. It serves healthcare providers across Europe and is expanding into the U.S.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, contract manufacturing, active pharmaceutical ingredients, rare disease treatments, infusion therapies
Industry2 codes
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Specialty Pharmaceuticals
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Products
TypeOne Time License
Description

ESTEVE develops and commercializes proprietary pharmaceutical products across specialty therapeutic areas including rare diseases (Cushing's syndrome, adrenocortical carcinoma), infusion therapies (Prialt for severe chronic pain, Quzyttir for acute urticaria), and supportive cancer care (AKYNZEO, ALOXI for chemotherapy-induced nausea and vomiting). Revenue is generated through product sales in global markets, with strong European presence and expanding U.S. footprint following acquisitions.

prnewswire.com
2CDMO Services (Contract Development and Manufacturing)
TypeProfessional Services
Description

ESTEVE CDMO provides contract development and manufacturing services for small-molecule APIs and pharmaceutical intermediates to pharmaceutical companies globally. Revenue is generated through service contracts and manufacturing fees. The business is expanding with new facilities in the USA and Spain, adding early development capabilities and spray drying capacity.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1ESTEVE CDMO
Description

Global contract development and manufacturing organization specializing in high-quality small-molecule APIs and pharmaceutical intermediates

esteve.com
Core offering1 text field

ESTEVE operates a dual-engine business combining proprietary specialty pharmaceuticals (rare disease treatments, infusion therapies, and supportive cancer care products such as Prialt, Quzyttir, AKYNZEO, and ALOXI) with a pure-play contract development and manufacturing (CDMO) organization specializing in small-molecule active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and high-potency APIs (HP APIs) for pharmaceutical companies globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Net revenue of €828 million in 2025 (+14% YoY)
+2 more records
Product overview1 text field

ESTEVE is a specialty pharmaceutical company operating two core business units: Pharma and CDMO Services. The Pharma business encompasses a portfolio of specialty medications including rare disease treatments (HRA Pharma Rare Diseases), severe chronic pain therapy (Prialt®), acute urticaria treatment (Quzyttir®), and supportive cancer care products (AKYNZEO®, ALOXI®). The CDMO Services business is a pure-play contract development and manufacturing organization specializing in small-molecule APIs and pharmaceutical intermediates, with capabilities including HPAPI manufacturing, spray drying, containment, and expansion into biologics. The company has grown through aggressive inorganic acquisition, integrating eight new products over 18 months and expanding CDMO capacity through facilities in Spain, China, and the United States.

Product and service3 records
1ESTEVE Pharma
CategorySpecialty Pharmaceuticals
Description

Specialty pharmaceutical business focused on therapeutic solutions in rare diseases, severe chronic pain, and supportive cancer care. Portfolio includes both internally developed and acquired brands marketed across Europe and the United States.

2ESTEVE CDMO
CategoryContract Development and Manufacturing
Description

Global contract development and manufacturing organization (CDMO) offering services including early development, spray drying, containment capabilities, and HPAPI manufacturing for pharmaceutical company clients globally. Facilities in Spain, the United States, and China.

3HRA Pharma Rare Diseases Portfolio
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-09
Description

ESTEVE and Helsinn expanded their partnership by extending their Distribution and Licence Agreement for AKYNZEO and ALOXI to Austria. The two companies have collaborated for over 15 years with previous agreements covering Germany, strengthening their presence in the German-speaking region for supportive cancer care treatments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

ESTEVE acquired TerSera Therapeutics' Infusion Specialty Therapies Business Unit, gaining worldwide rights (excluding China) to Quzyttir and consolidating global rights for Prialt. The deal closed in Q1 2026 and marked ESTEVE's strategic expansion into the U.S. pharmaceutical market.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

In July 2025, ESTEVE acquired U.S.-based Regis Technologies Inc., a CDMO specializing in high-potency APIs. The acquisition was aimed at bolstering ESTEVE's U.S. footprint and manufacturing capabilities in the HP API space.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-10
Description

ESTEVE completed the acquisition of HRA Pharma Rare Diseases from Perrigo for up to €275 million (€190M upfront + earnouts). The acquisition expanded ESTEVE's rare disease portfolio including treatments for Cushing's syndrome and adrenocortical carcinoma, accelerating its international growth.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Swiss-headquartered global CDMO leader operating across small molecules, biologics, and cell/gene therapy manufacturing. Competes with ESTEVE CDMO in API manufacturing with significantly larger scale and broader service portfolio.

TypeEmerging player
Description

Swiss specialty pharmaceutical company focused on supportive cancer care (including AKYNZEO and ALOXI that ESTEVE distributes in Europe). Comparable to ESTEVE's supportive cancer care segment and serves as both partner and adjacent specialty pharma peer.

TypeDirect peer
Description

Spanish specialty pharmaceutical company focused on dermatology and rare diseases with established European commercial footprint. Comparable to ESTEVE's specialty pharma arm, particularly its rare disease portfolio acquired through HRA Pharma.

TypeDirect peer
Description

Spanish specialty pharmaceutical company with focus on prescription pharma, OTC, and animal health across European markets. Comparable to ESTEVE's specialty pharma segment as a similarly-sized Spanish player pursuing growth through specialty therapeutic areas.

TypeDirect peer
Description

US-based CDMO specializing in small-molecule APIs and finished dosage forms with HP API capabilities. Direct competitor to ESTEVE CDMO in the high-potency API manufacturing space, particularly relevant given ESTEVE's US expansion through Regis Technologies acquisition.

TypeDirect peer
Description

Spanish specialty pharmaceutical company operating both proprietary pharma and CDMO services, with a similar dual-engine model serving European and select international markets. Closest comparable to ESTEVE given shared Spanish heritage, specialty pharma focus, and contract manufacturing capabilities.

TypeBroad incumbent
Description

Global CDMO leader (now owned by Novo Holdings) with broad capabilities across small molecules, biologics, and cell/gene therapies. Larger incumbent competing with ESTEVE CDMO in small-molecule API manufacturing with significantly broader scale and geographic reach.

8Recipharm
TypeDirect peer
Description

European CDMO specializing in small-molecule APIs and finished dosage forms with facilities across Europe. Direct competitor to ESTEVE CDMO in the contract manufacturing of small-molecule APIs and pharmaceutical intermediates for global pharmaceutical clients.

TypeBroad incumbent
Description

Italian specialty pharmaceutical company with focus on rare diseases, respiratory, and specialty therapeutics with global commercial presence. Comparable to ESTEVE's specialty pharma arm as a larger European specialty pharma with established rare disease capabilities.

TypeBroad incumbent
Description

Italian specialty pharmaceutical company with focus on rare diseases and specialty therapeutics across global markets. Comparable to ESTEVE's specialty pharma arm as a larger European specialty pharma competitor in rare disease and specialty therapeutic areas.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ESTEVE

Specialty Pharmaceuticalsesteve.es

ESTEVE is a Barcelona-based private specialty pharmaceutical company operating a dual-engine model: proprietary drugs in rare diseases, infusion therapies, and supportive cancer care, plus a global CDMO business specializing in small-molecule APIs and high-potency APIs. It serves healthcare providers across Europe and is expanding into the U.S.

What ESTEVE does

ESTEVE is a privately held Spanish specialty pharmaceutical company headquartered in Barcelona that operates a dual-engine business model combining proprietary pharmaceutical products with contract development and manufacturing (CDMO) services. The company employs between 1,001 and 5,000 people and reported €828 million in 2025 net revenue (+14% YoY) alongside €151 million in EBITDA (+19% YoY) at an 18% margin, with management targeting €1 billion in revenue by 2027.

On the pharmaceutical side, ESTEVE commercializes specialty medications across rare diseases (Cushing's syndrome, adrenocortical carcinoma via the HRA Pharma Rare Diseases portfolio acquired from Perrigo in 2024), infusion therapies (Prialt for severe chronic pain and Quzyttir for acute urticaria, consolidated globally via the March 2026 TerSera acquisition), and supportive cancer care (AKYNZEO and ALOXI for chemotherapy-induced nausea and vomiting, distributed in DACH markets under a 15-year partnership with Helsinn Healthcare). The company sells these products through a direct enterprise sales force covering seven European markets — Spain, France, Germany, Italy, Portugal, the UK, and Benelux — and is now expanding into the United States following the TerSera acquisition.

On the CDMO side, ESTEVE CDMO is a global pure-play contract development and manufacturing organization specializing in high-quality small-molecule active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and high-potency APIs (HP APIs) used in oncology and hormonal therapies. Capabilities were significantly expanded through the July 2025 acquisition of U.S.-based Regis Technologies and a $15.5 million investment in the Morton Grove, Illinois facility announced in March 2026, alongside the addition of spray dryers and containment capabilities at the Celrà, Girona, Spain site. The company has cumulatively deployed approximately €500 million in inorganic investments over two years, is partially owned (26% stake) by German private investment firm Lubea since May 2023, and achieved B Corp Certification in January 2026.

ESTEVE firmographics

Firmographics
Name
ESTEVE
Legal name
ESTEVE
Website
https://esteve.es
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
ESTEVE is a Barcelona-based private specialty pharmaceutical company operating a dual-engine model: proprietary drugs in rare diseases, infusion therapies, and supportive cancer care, plus a global CDMO business specializing in small-molecule APIs and high-potency APIs. It serves healthcare providers across Europe and is expanding into the U.S.
Ownership category
akta.pro rank

ESTEVE industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Specialty pharmaceuticals
  • Contract manufacturing
  • Active pharmaceutical ingredients
  • Rare disease treatments
  • Infusion therapies

Where ESTEVE is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Offices3 records

Markets served

ESTEVE business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations

Revenue model

  1. Pharmaceutical Products: ESTEVE develops and commercializes proprietary pharmaceutical products across specialty therapeutic areas including rare diseases (Cushing's syndrome, adrenocortical carcinoma), infusion therapies (Prialt for severe chronic pain, Quzyttir for acute urticaria), and supportive cancer care (AKYNZEO, ALOXI for chemotherapy-induced nausea and vomiting). Revenue is generated through product sales in global markets, with strong European presence and expanding U.S. footprint following acquisitions.
  2. CDMO Services (Contract Development and Manufacturing): ESTEVE CDMO provides contract development and manufacturing services for small-molecule APIs and pharmaceutical intermediates to pharmaceutical companies globally. Revenue is generated through service contracts and manufacturing fees. The business is expanding with new facilities in the USA and Spain, adding early development capabilities and spray drying capacity.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

ESTEVE product offering

Product offering

Core offering

ESTEVE operates a dual-engine business combining proprietary specialty pharmaceuticals (rare disease treatments, infusion therapies, and supportive cancer care products such as Prialt, Quzyttir, AKYNZEO, and ALOXI) with a pure-play contract development and manufacturing (CDMO) organization specializing in small-molecule active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and high-potency APIs (HP APIs) for pharmaceutical companies globally.

Product overview

ESTEVE is a specialty pharmaceutical company operating two core business units: Pharma and CDMO Services. The Pharma business encompasses a portfolio of specialty medications including rare disease treatments (HRA Pharma Rare Diseases), severe chronic pain therapy (Prialt®), acute urticaria treatment (Quzyttir®), and supportive cancer care products (AKYNZEO®, ALOXI®). The CDMO Services business is a pure-play contract development and manufacturing organization specializing in small-molecule APIs and pharmaceutical intermediates, with capabilities including HPAPI manufacturing, spray drying, containment, and expansion into biologics. The company has grown through aggressive inorganic acquisition, integrating eight new products over 18 months and expanding CDMO capacity through facilities in Spain, China, and the United States.

Differentiator

Problem solved

Functional benefit

Brands

  • ESTEVE CDMO: Global contract development and manufacturing organization specializing in high-quality small-molecule APIs and pharmaceutical intermediates

Products and services

  • ESTEVE Pharma Specialty pharmaceutical business focused on therapeutic solutions in rare diseases, severe chronic pain, and supportive cancer care. Portfolio includes both internally developed and acquired brands marketed across Europe and the United States.
  • ESTEVE CDMO Global contract development and manufacturing organization (CDMO) offering services including early development, spray drying, containment capabilities, and HPAPI manufacturing for pharmaceutical company clients globally. Facilities in Spain, the United States, and China.
  • HRA Pharma Rare Diseases Portfolio

Quantifiable outcome

  • Net revenue of €828 million in 2025 (+14% YoY)
  • +2 more outcomes

Companies that use ESTEVE

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

ESTEVE technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

ESTEVE partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Helsinn Healthcare SAcoreChannel Partner/ Reseller/ Distributor · 9 February 2026ESTEVE and Helsinn expanded their partnership by extending their Distribution and Licence Agreement for AKYNZEO and ALOXI to Austria. The two companies have collaborated for over 15 years with previous agreements covering Germany, strengthening their presence in the German-speaking region for supportive cancer care treatments.
  • TerSera TherapeuticscoreStrategic or Co-development Partner · 13 January 2026ESTEVE acquired TerSera Therapeutics' Infusion Specialty Therapies Business Unit, gaining worldwide rights (excluding China) to Quzyttir and consolidating global rights for Prialt. The deal closed in Q1 2026 and marked ESTEVE's strategic expansion into the U.S. pharmaceutical market.
  • Regis Technologies Inc.coreStrategic or Co-development Partner · 1 July 2025In July 2025, ESTEVE acquired U.S.-based Regis Technologies Inc., a CDMO specializing in high-potency APIs. The acquisition was aimed at bolstering ESTEVE's U.S. footprint and manufacturing capabilities in the HP API space.
  • Perrigo Company plccoreStrategic or Co-development Partner · 10 July 2024ESTEVE completed the acquisition of HRA Pharma Rare Diseases from Perrigo for up to €275 million (€190M upfront + earnouts). The acquisition expanded ESTEVE's rare disease portfolio including treatments for Cushing's syndrome and adrenocortical carcinoma, accelerating its international growth.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

ESTEVE competitors and assessment

Company assessment

Broad incumbents

  • Lonza Group: Swiss-headquartered global CDMO leader operating across small molecules, biologics, and cell/gene therapy manufacturing. Competes with ESTEVE CDMO in API manufacturing with significantly larger scale and broader service portfolio.
  • Catalent: Global CDMO leader (now owned by Novo Holdings) with broad capabilities across small molecules, biologics, and cell/gene therapies. Larger incumbent competing with ESTEVE CDMO in small-molecule API manufacturing with significantly broader scale and geographic reach.
  • Chiesi Farmaceutici: Italian specialty pharmaceutical company with focus on rare diseases, respiratory, and specialty therapeutics with global commercial presence. Comparable to ESTEVE's specialty pharma arm as a larger European specialty pharma with established rare disease capabilities.
  • Recordati: Italian specialty pharmaceutical company with focus on rare diseases and specialty therapeutics across global markets. Comparable to ESTEVE's specialty pharma arm as a larger European specialty pharma competitor in rare disease and specialty therapeutic areas.

Emerging players

  • Helsinn Healthcare: Swiss specialty pharmaceutical company focused on supportive cancer care (including AKYNZEO and ALOXI that ESTEVE distributes in Europe). Comparable to ESTEVE's supportive cancer care segment and serves as both partner and adjacent specialty pharma peer.

Direct peers

  • Almirall: Spanish specialty pharmaceutical company focused on dermatology and rare diseases with established European commercial footprint. Comparable to ESTEVE's specialty pharma arm, particularly its rare disease portfolio acquired through HRA Pharma.
  • Faes Farma: Spanish specialty pharmaceutical company with focus on prescription pharma, OTC, and animal health across European markets. Comparable to ESTEVE's specialty pharma segment as a similarly-sized Spanish player pursuing growth through specialty therapeutic areas.
  • Cambrex: US-based CDMO specializing in small-molecule APIs and finished dosage forms with HP API capabilities. Direct competitor to ESTEVE CDMO in the high-potency API manufacturing space, particularly relevant given ESTEVE's US expansion through Regis Technologies acquisition.
  • Laboratorios Farmaceuticos Rovi: Spanish specialty pharmaceutical company operating both proprietary pharma and CDMO services, with a similar dual-engine model serving European and select international markets. Closest comparable to ESTEVE given shared Spanish heritage, specialty pharma focus, and contract manufacturing capabilities.
  • Recipharm: European CDMO specializing in small-molecule APIs and finished dosage forms with facilities across Europe. Direct competitor to ESTEVE CDMO in the contract manufacturing of small-molecule APIs and pharmaceutical intermediates for global pharmaceutical clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

ESTEVE social profiles

Digital presence

ESTEVE compliance and trust

Trust signal

Compliance1 record

ESTEVE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ESTEVE leadership team

Management profile

Number of profiles

Profiles3 records

ESTEVE subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

ESTEVE funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ESTEVE M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ESTEVE

What does ESTEVE do?

ESTEVE operates a dual-engine business combining proprietary specialty pharmaceuticals (rare disease treatments, infusion therapies, and supportive cancer care products such as Prialt, Quzyttir, AKYNZEO, and ALOXI) with a pure-play contract development and manufacturing (CDMO) organization specializing in small-molecule active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and high-potency APIs (HP APIs) for pharmaceutical companies globally.

Is ESTEVE a public or private company?

ESTEVE is a private company. It is classified as private equity controlled and is currently operating.

When was ESTEVE founded?

ESTEVE was founded in 1996. It employs 1,001 to 5,000 people.

Where is ESTEVE based?

ESTEVE is headquartered in Barcelona, Spain, in the Europe region.

How does ESTEVE make money?

Two revenue lines are on record. Pharmaceutical Products are the primary driver. The others are CDMO Services (Contract Development and Manufacturing).

Who are ESTEVE's main competitors?

Broad incumbents on record are Lonza Group, Catalent, Chiesi Farmaceutici and Recordati. Helsinn Healthcare is listed as an emerging player. Direct peers are Almirall, Faes Farma, Cambrex, Laboratorios Farmaceuticos Rovi and Recipharm.

Does ESTEVE have an API?

No public API is recorded for ESTEVE.

What industry is ESTEVE in?

ESTEVE's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nate[PRNewswire] 에스테베 CDMO, 중국 신규 제조 시설에 대규모 투자로 입지 강화 : 네이트 뉴스Esteve CDMO is investing over $80 million in a new manufacturing facility in Shaoxing, China, to expand its Asia presence. The facility has a 250 cubic meter reaction capacity with potential to expand to over 400 cubic meters, incorporating advanced automation and digital transformation. The company aims to strengthen its global network and support growing API manufacturing complexity.Pulse 2.0ESTEVE CDMO Invests More Than $80 Million In New China Manufacturing SiteESTEVE CDMO is investing over $80 million to build a new manufacturing facility in Shaoxing, China, with three workshops totaling 250 cubic meters of reaction volume. The site includes advanced automation and a BREEAM 'Very Good' rating, and reserves space for future capacity to exceed 400 cubic meters.FiercePharmaEsteve earmarks $80M to revamp CDMO operations in ChinaEsteve CDMO announced an $80 million investment to relocate and expand its China manufacturing footprint, adding three new workshops in Shaoxing. The new site reserves 150 m³ of reactor volume, potentially reaching over 400 m³ total, to support Asia's growing demand for small-molecule API development.PR NewswireESTEVE CDMO renforce sa présence mondiale dans le domaine de la fabrication grâce à un investissement majeur et à l'ouverture d'un nouveau site en ChineESTEVE CDMO invested over $80 million to expand its Chinese manufacturing presence, opening a new Shaoxing site with three production sites totaling 250 m³ of reaction volume. The site, certified BREEAM 'Very Good', aims to reach over 400 m³ potential capacity and strengthens its global network.EXPANSIONEsteve invierte 71 millones en ampliar y modernizar su planta de ChinaEsteve invested 80 million dollars in relocating, expanding, and modernizing its CDMO facilities in Shaoxing, China. The company reported 828 million euros in revenue for 2025, with the CDMO division contributing 58%. It also announced a 100 million euro investment in a second plant in Celrà.Nate[PRNewswire] ESTEVE CDMO expands its presence in Asia : 네이트 뉴스ESTEVE CDMO is investing over $80 million to relocate and expand its China manufacturing operations in Shaoxing. The new facility has a 250 m³ reaction volume with potential capacity exceeding 400 m³, and includes advanced automation and digitalization. The project aims to strengthen ESTEVE's presence in Asia and support customers across the region.Business & FinancialESTEVE CDMO Strengthens Its Global Manufacturing Footprint With A Major Investment And New Site In ChinaESTEVE CDMO invested over $80 million to expand its China manufacturing operations, adding three workshops with 250 m3 total reaction volume. The new Shaoxing facility includes advanced automation and a BREEAM 'Very Good' rating, with capacity reserved for 400+ m3. The investment builds on ESTEVE's 20-year presence in China.PR Newswire APACESTEVE CDMO expands its presence in Asia with a major investment and new manufacturing site in ChinaESTEVE CDMO is investing over $80 million to relocate and expand its China manufacturing operations, opening a new facility in Shaoxing. The site includes three workshops with a 250 m³ reaction volume, expandable to over 400 m³, and has achieved a BREEAM 'Very Good' rating.PR Newswire APACESTEVE CDMO expands its presence in Asia with a major investment and new manufacturing site in ChinaESTEVE CDMO is investing over $80 million to expand its China manufacturing presence, relocating and modernizing operations in Shaoxing. The new facility has a 250 m³ reaction volume with potential capacity exceeding 400 m³, and achieved a 'Very Good' BREEAM rating.Third NewsESTEVE CDMO Enhances Global Manufacturing with $80 Million Investment in ChinaESTEVE CDMO announced an investment exceeding $80 million to expand its China manufacturing footprint, including a new site in Shaoxing. The new facility has three production halls with a total reaction volume of 250 m³, expandable to over 400 m³. The project received a BREEAM 'Very Good' rating and is a candidate for BREEAM China Awards.